title: Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients.
abstract: BACKGROUND
  To determine the risk of arterial and venous thromboembolic events (ATEs and VETs) associated with anti-epidermal growth factor receptor (EGFR) agents in non-small-cell lung cancer (NSCLC) patients.
  
  
  METHODS
  Prospective randomized trials evaluating therapy with or without anti-EGFR agents in NSCLC patients. Data on VTEs and ATEs were extracted.
  
  
  RESULTS
  A total of 8,410 patients from 12 trials were included for analysis. Anti-EGFR agents significantly increased the risk of all-grade and high-grade VTEs (Peto OR 1.50, 95%CI 1.16-1.95, P = 0.002; Peto OR 1.73, 95%CI: 1.32-2.26, p < 0.001, respectively), but not for all-grade and high-grade ATEs.
  
  
  CONCLUSIONS
  The use of anti-EGFR agents significantly increased the risk of all-grade and high-grade VTEs but not for ATEs in NSCLC patients.
authors: a Liaoning Cancer Hospital & Insititute, Third Department of Internal Medicine , Cancer Hospital of China Medical University , Shenyang , China.
authors: Jian
authors: J
authors: Zheng
authors: b Liaoning Cancer Hospital & Insititute, The department of medical imaging , Cancer Hospital of China Medical University , Shenyang , China.
authors: Xiaoru
authors: X
authors: Bai
authors: a Liaoning Cancer Hospital & Insititute, Third Department of Internal Medicine , Cancer Hospital of China Medical University , Shenyang , China.
authors: Chengyu
authors: C
authors: Hong
authors: a Liaoning Cancer Hospital & Insititute, Third Department of Internal Medicine , Cancer Hospital of China Medical University , Shenyang , China.
authors: Hong
authors: H
authors: Gao
authors: a Liaoning Cancer Hospital & Insititute, Third Department of Internal Medicine , Cancer Hospital of China Medical University , Shenyang , China.
authors: Xiaoling
authors: X
authors: Li
keywords: Anti-EGFR agents; arterial thromboembolic events; meta-analysis; venous thromboembolic events